MedTrace Logo

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

NCT06238024 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2024-09-25

No results posted yet for this study

Summary

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Conditions

Interventions

DRUG

Tocilizumab

Single dose intravenous application

DRUG

NaCl 0.9% 100ml

Single dose intravenous application

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • Suzhou Municipal Hospital of Anhui Province

    lead OTHER

Principal Investigators

  • Chuanjie Wu, M.D. · Xuanwu Hospital, Beijing

  • Zhengfei Ma, M.M. · Suzhou Municipal Hospital of Anhui Province

  • Xunming Ji, M.D. · Xuanwu Hospital, Beijing

  • Xuehong Chu, M.D. · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2024-06-25
Completion
2024-09-22

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238024 on ClinicalTrials.gov